CD274 and non-small cell lung carcinoma: In a retrospective study of 40 NSCLC patients undergoing nivolumab treatment, the 28-8, 22C3, and SP263 PD-L1 IHC assays showed equivalent predictive performance, whereas the SP142 assay showed lower predictive performance [23].